Biomarkers are biological indicators of early disease detection (diagnostic), disease progression and outcome (prognostic), and response to therapy (predictive).
Tumor cells employ a variety of different strategies to evade the host immune attack. The immune reactivity of a tumor is a measure of its inflammatory state, which is determined by a combination of tumor-intrinsic and host-derived factors.
Mr. Nemzek has held executive senior leadership team positions in both public companies and a number of private companies that have become successful public companies by merger and acquisition.
The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.
This arrangement seamlessly integrates MedGenome’s cancer immunotherapy genomics platform with ZellNet’s immune monitoring services. This partnership will facilitate present customers of ZellNet’s immune monitoring services to quickly expand their cancer immunotherapy research into the genomics space by leveraging the power of next-generation sequencing-based approaches of neo-antigen and neo-epitope prediction.